President Donald Trump in a press conference on Thursday said the Food and Drug Administration is fast-tracking efforts to approve an antiviral therapy, best known for treating malaria, for use in coronavirus cases. 

The drug, hydroxychloroquine, was developed more than a half-century ago and is approved for treating malaria, arthritis, and other ailments. Reports out of China and Italy suggest the drug may help, but there is no hard data yet.

"We're going to be able to make that drug available almost immediately," Trump said. 

The FDA is working to conduct a "large, pragmatic clinical trial" quickly to confirm the drug's benefit to coronavirus patients, said Commissioner Dr. Stephen Hahn.

He also tempered the president's optimism about the still-untested solution. 

"What's also important is not to provide false hope," he said. "We may have the right drug, but it might not be in the appropriate dosage form right now, and it might do more harm than good."

New antiviral therapies face a shorter and less arduous approval process than vaccines, several of which are under development with 12 to 18-month timelines.  

"The therapies are something we could move on much faster potentially," Trump said. 

He claimed the administration "slashed red tape" to develop new vaccines and therapies.

The president also held out on confirming whether he would invoke the Defense Production Act, which he signed on Wednesday, to mandate the production of needed medical supplies such as N95 respirators and surgical masks

"If we find that we need something, then we will do that," he said.  

Trump repeated that he was open to the federal government buying equity stakes in the airline, cruise, hospitality, and other industries hurt by the outbreak. 

The press conference opened with more controversial language placing the blame squarely on China for the outbreak, despite concerns voiced about potentially exacerbating a backlash against Asian Americans.

"We continue our relentless effort to defeat the Chinese virus," Trump said.

Share:
More In Politics
Yelp to Cover Travel Expenses for Workers Seeking Abortions
This March 19, 2018, file photo shows the Yelp app on an iPad in Baltimore. Yelp reports financial results Thursday, Nov. 7, 2019. The online review service will cover the travel expenses of employees who have to travel out of state for abortions, joining the ranks of major employers trying to help workers affected by restrictions being placed on the procedure in Texas and other states. The benefit announced Tuesday, April 12, 2022 covers Yelp's entire workforce of 4,000 employees, but seems most likely to have its biggest immediate impact on its 200 workers in Texas, which has passed a law banning abortions within the state after six weeks of pregnancy. (AP Photo/Patrick Semansky, File)
Former DOJ Agent on Investigation Into Brooklyn Subway Mass Shooting
David Katz, a former federal agent with the Department of Justice, and currently founder, CEO, and owner of Global Security Group, joined Cheddar News to talk about the Tuesday mass shooting on a subway train in Brooklyn, N.Y. even as local authorities have so far stated it was not being investigated as a potential terrorist attack. "At this point between the commissioner of the NYPD and the governor of New York, they're almost saying, 'well, it's an active shooter incident.' Okay, but active shooter incidents can also be motivated by terrorism, so until we know motive, we can't make that conclusion at all," Katz said.
U.S. Stocks Turn Positive in Final Hour to Close Higher
U.S. stocks saw a jump in the final hour of Thursday's session, and ultimately closed slightly higher for the day. Tim Pagliara, Chief Investment Officer of CapWealth, joined Cheddar News' Closing Bell to discuss. "The markets have had to digest a lot of action from the federal reserve this quarter and it's affecting everything from mortgage rates to how they value stocks," he said.
Load More